News: Medicine

View:

2009

 

Found press releases

 

FDA accepts NDA filing for Retigabine

12/30/2009 8:07 AM EST  -   MEDA
The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.

Retigabine comprises a new way of affecting potassium channels in the...

Meda expands Axorid collaboration

12/30/2009 4:00 AM EST  -   MEDA
Meda expands the collaboration with the French development company Etypharm for the patented product Axorid. New territories, such as East Europe with Russia and Turkey, are now included in the collaboration. Previously, Meda held commercialization rights in Central and West Europe.

Axorid consists of the well-known and broadly used substances; ketoprofen, a NSAID (Non Sterodial Anti-Inflammatory Drug) for the...

NEW NUMBER OF SHARES AND VOTES IN KARO BIO AB (PUBL)

12/30/2009 2:30 AM EST  -   Karo Bio
STOCKHOLM, December 30, 2009. Karo Bio AB (publ) (Reuters: KARO.ST) today announced that the company’s total number of shares as per December 30, 2009 amounts to 154,825,589 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from an issue of 38,706,397 shares under Karo Bio’s rights issue that was announced on October 26, 2009.



For more information please...
manufacturing awards
 

ELEKTA WINS WORLD CLASS MANUFACTURING AWARD

12/29/2009 4:00 AM EST  -   Elekta
Elekta, the world-leading manufacturer of treatment solutions for cancer and brain disorders, has been awarded the prestigious World Class Manufacturing award by The Manufacturer magazine. The award was given in recognition of the quality work produced each year by Elekta manufacturing staff.
Elekta’s U.K. office began implementing Lean processes for manufacturing and product development in 2007, focusing on...

MOBERG DERMA CLOSED TRANCHE 2 OF FINANCING

12/22/2009 4:48 AM EST  -   MOBERG DERMA AB
The pharmaceutical company Moberg Derma completed the second tranche of its share issue according to plan. During 2009, a total of SEK 40 million has been secured. The second tranche of SEK 10 million was directed primarily to existing shareholders. More than SEK 110 million has been raised since the company was established in March 2006.

“We are very pleased with the strong support from our investors. Through the...

FINANCIAL CALENDER FOR 2010

12/21/2009 9:11 AM EST  -   DiaGenic ASA
4th quarter results 2009 and preliminary annual result for 2009: 25 February 2010 1st quarter results 2010: 20 May 2010 Annual General Meeting: 3 June2010 2nd quarter results 2010: 19 August 2010 3rd quarter results 2010: 29 October 2010 This information is subject to disclosure requirements according to §5-12 vphl (Norwegian Securities Trading Act)

EXTRAORDINARY GENERAL MEETING HELD IN DIAGENIC ASA

12/18/2009 6:16 AM EST  -   DiaGenic ASA
The extraordinary general meeting of DiaGenic ASA was held on 18 December 2009.

The general meeting resolved share capital increase by issue of new shares and issue of warrants, in accordance with the proposals set forth in the notice.

The minutes from the extraordinary general meeting will be available at www.newsweb.no and www.diagenic.com.


MD PhD Erik Christensen, Managing Director
Telephone: +47...
Likvor CELDA
 

Likvor receives an order for CELDA from Uppsala University Hospital

12/11/2009 5:21 AM EST  -   Likvor
Likvor has received an order for Likvor CELDA™ from Uppsala University Hospital (Akademiska Universitetssjukhuset). With Likvor CELDA™ the clinical will be able to dynamic measure the most important parameters concerning the patients’ cerebrospinal fluid including pressure and flow. Likvor CELDA™ was developed to facility greater understanding and enhancing diagnosis of normal pressure hydrocephalus (NPH), a...

Six-month interim report May – October 2009/10

12/10/2009 7:00 AM EST  -   Elekta
• Order bookings increased 20* percent.
• Net sales rose 10* percent to SEK 3,131 M (2,492).
• Operating profit increased to SEK 321 M (118).
• Profit after taxes rose to SEK 211 M (59).
• Earnings per share after dilution improved to SEK 2.32 (0.67).
• Postitive cash flow from operating activities, improved to SEK 150 M (neg. 95).
Cash flow after investments was positive SEK 104 M (neg. 180).
• Elekta’s financial...

KARO BIO’S RIGHTS ISSUE SUBSTANTIALLY OVERSUBSCRIBED

12/9/2009 2:30 AM EST  -   Karo Bio
Not for release, publication or distribution in Australia, Canada, Japan or the United States. This announcement does not constitute an offer to sell or the solicitation of an offer to buy the securities of Karo Bio AB (publ) (the “Securities”) in Australia, Canada, Japan or the United States or in any other jurisdiction. Securities may not be offered or sold in the United States absent registration or an exemption...